Daniel Thomson
South Australian Immunogenomics Cancer Institute
Faculty of Health and Medical Sciences
Dr Daniel Thomson is a computational/molecular biologist passionate about applying genomic technology for cancer research and new diagnostic tests. Joining SAIGENCI in 2025, Daniel is using genomic and transcriptomic approaches to understand mechanisms of cancer therapy resistance, in order to develop new bioinformatic tools to predict patient outcomes.
He has held postdoctoral positions at the Garvan Institute, SA Pathology and Flinders University, and has a proven capacity to translate research findings into clinical diagnostic applications, having lead the bioinformatic development and NATA accreditation of multiple genomic tests currently in the clinic. This includes development of variant and fusion-gene calling pipelines for solid and haematological tumours as lead clinical bioinformatician at Monash Pathology, and a polygenic risk score for glaucoma predisposition testing at an Adelaide-based biotech start-up SeonixBio,
With proven expertise in genomic computational biology in research and biotech industry roles, Daniel is highly motivated with strong research background ( 25 research publications, >4000 citations), This includes first author publications in Nature Reviews Genetics, Nucleic Acids Research and Leukaemia.
-
Appointments
Date Position Institution name 2025 - ongoing Senior Postdoctoral Researcher SAIGENCI 2023 - 2025 Senior Bioinformatician South Australian Genomic Centre 2020 - 2021 Clinical Bioinformatics Lead Monash Health 2017 - 2020 Research Scientist SAPathology 2014 - 2017 Postdoctoral researcher Garvan Institute of Medical Research 2011 - 2023 Senior Bioinformatician SeonixBio -
Education
Date Institution name Country Title 2010 - 2014 University of Adelaide Australia PhD -
Research Interests
-
Journals
-
Conference Papers
Year Citation 2019 Shanmuganathan, N., Thomson, D., Wadham, C., Saunders, V. A., Shahrin, N. H., Yeung, D. T., . . . Branford, S. (2019). RNA Splicing Defects in Cancer-Linked Genes Indicate Mutation or Focal Gene Deletion and Are Associated with TKI Resistance in CML. In BLOOD Vol. 134 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS12019 Branford, S., Wadham, C., Shanmuganathan, N., Thomson, D., Shahrin, N. U. R. H., Feng, J., . . . Hughes, T. P. (2019). An RNA-Based Next Generation Sequencing (NGS) Strategy Detects More Cancer Gene Mutations Than a DNA-Based Approach for the Prediction and Assessment of Resistance in CML. In BLOOD Vol. 134 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI2019 Shahrin, N. H., Thomson, D., Wadham, C., Schreiber, A., & Branford, S. (2019). IMATINIB INDUCES MARKED UPREGULATION OF RECOMBINATION ACTIVATING GENE (RAG) EXPRESSION IN BCR-ABL1 POSITIVE LYMPHOID CELLS. In EXPERIMENTAL HEMATOLOGY Vol. 76 (pp. S85). ELSEVIER SCIENCE INC. 2018 Thomson, D., Shahrin, H., Wang, P., Wadham, C., Hughes, T. P., Schreiber, A., & Branford, S. (2018). High Recombination Activating Gene (RAG) Expression and RAG Mediated Recombination Is Associated with Oncogenic Rearrangement Observed with Tyrosine Kinase Inhibitor Resistant CML. In BLOOD Vol. 132 (pp. 4 pages). CA, San Diego: AMER SOC HEMATOLOGY.
DOI WoS1 -
Conference Items
Connect With Me
External Profiles